News
New regimen for hepatitis C genotype 2 beats previous standard of care
A two-drug regimen without ribavirin was found superior to the current standard of care for genotype 2 (GT2) hepatitis C virus infection,...
News
Proportion of HCV patients in U.S. with cirrhosis climbing
Key clinical point: Despite a national decline in the prevalence of hepatitis C virus infection, the prevalence of cirrhosis among HCV-infected...
News
AASLD: HCV cure associated with reduction in all-cause mortality
Sustained virologic response in patients with hepatitis C virus infection is associated with large reductions in all-cause mortality and appears...
News
Elevated liver cancer risk after HCV cure may justify surveillance
Sustained virologic response in patients with well controlled hepatic C virus infection does not protect select subgroups of this cohort from...
News
Investigational hepatitis B therapy shows activity in proof-of-concept study
NVR 3-778, an experimental hepatitis B virus core inhibitor, showed substantial activity and was well tolerated in an initial phase Ib study.
News
Sofosbuvir/R yields benefits in compassionate use HCV program
In real-world setting, sofosbuvir in combination with ribavirin (SOF/R) provided meaningful benefits for special populations with hepatitis C...
News
Multitargeted drug combination promising when new HCV antivirals fail
Key clinical point: A five-drug antiviral combination appears to be effective for retreatment of patients with hepatitis C virus infection who...
News
Regimen effective in genotype 3 HCV despite advanced cirrhosis
Sustained virologic response in patients with genotype 3 hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis was achieved in 88%...
News
Cellular therapy benefit limited to young alcoholic hepatitis patients
The only patients with alcoholic hepatitis to derive a survival benefit from extracorporeal hepatocellular therapy with C3A hepatoma cells were...
News
High SVR achieved in decompensated HCV patients with 12-week therapy
The findings are encouraging because current treatment options for patients with HCV who have decompensated liver disease are limited, Dr....
News
New direct-acting antivirals for HCV perform well in real world
Discontinuation rates for the new direct-acting antivirals are “not a major issue” in real world clinical practice.
News
Eight-week, three-drug regimen produces SVR over 90% in HCV
A triple antiviral combination with direct-acting antiviral agents was associated with high rates of sustained virologic response across all three...
News
Pan-caspase inhibitor controls cirrhosis-associated portal hypertension
Emricasan, a caspase inhibitor, achieves a significant reduction in portal pressure among patients with cirrhosis and severe portal hypertension,...
News
Lusutrombopag is effective for thrombocytopenia in liver disease
Key clinical point: In a phase III trial, lusutrombopag was found to reduce the need for platelet transfusion in chronic liver disease patients...
News
AHA: Mixed results for mitral valve replacement vs. repair
Mitral valve replacement reduced regurgitation better than valve repair, but it didn’t significantly improve left ventricular function or survival...